• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

KRAS变异体rs61764370对卵巢癌或乳腺癌无临床应用价值。

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

作者信息

Hollestelle Antoinette, van der Baan Frederieke H, Berchuck Andrew, Johnatty Sharon E, Aben Katja K, Agnarsson Bjarni A, Aittomäki Kristiina, Alducci Elisa, Andrulis Irene L, Anton-Culver Hoda, Antonenkova Natalia N, Antoniou Antonis C, Apicella Carmel, Arndt Volker, Arnold Norbert, Arun Banu K, Arver Brita, Ashworth Alan, Baglietto Laura, Balleine Rosemary, Bandera Elisa V, Barrowdale Daniel, Bean Yukie T, Beckmann Lars, Beckmann Matthias W, Benitez Javier, Berger Andreas, Berger Raanan, Beuselinck Benoit, Bisogna Maria, Bjorge Line, Blomqvist Carl, Bogdanova Natalia V, Bojesen Anders, Bojesen Stig E, Bolla Manjeet K, Bonanni Bernardo, Brand Judith S, Brauch Hiltrud, Brenner Hermann, Brinton Louise, Brooks-Wilson Angela, Bruinsma Fiona, Brunet Joan, Brüning Thomas, Budzilowska Agnieszka, Bunker Clareann H, Burwinkel Barbara, Butzow Ralf, Buys Saundra S, Caligo Maria A, Campbell Ian, Carter Jonathan, Chang-Claude Jenny, Chanock Stephen J, Claes Kathleen B M, Collée J Margriet, Cook Linda S, Couch Fergus J, Cox Angela, Cramer Daniel, Cross Simon S, Cunningham Julie M, Cybulski Cezary, Czene Kamila, Damiola Francesca, Dansonka-Mieszkowska Agnieszka, Darabi Hatef, de la Hoya Miguel, deFazio Anna, Dennis Joseph, Devilee Peter, Dicks Ed M, Diez Orland, Doherty Jennifer A, Domchek Susan M, Dorfling Cecilia M, Dörk Thilo, Silva Isabel Dos Santos, du Bois Andreas, Dumont Martine, Dunning Alison M, Duran Mercedes, Easton Douglas F, Eccles Diana, Edwards Robert P, Ehrencrona Hans, Ejlertsen Bent, Ekici Arif B, Ellis Steve D, Engel Christoph, Eriksson Mikael, Fasching Peter A, Feliubadalo Lidia, Figueroa Jonine, Flesch-Janys Dieter, Fletcher Olivia, Fontaine Annette, Fortuzzi Stefano, Fostira Florentia, Fridley Brooke L, Friebel Tara, Friedman Eitan, Friel Grace, Frost Debra, Garber Judy, García-Closas Montserrat, Gayther Simon A, Gentry-Maharaj Aleksandra, Gerdes Anne-Marie, Giles Graham G, Glasspool Rosalind, Glendon Gord, Godwin Andrew K, Goodman Marc T, Gore Martin, Greene Mark H, Grip Mervi, Gronwald Jacek, Gschwantler Kaulich Daphne, Guénel Pascal, Guzman Starr R, Haeberle Lothar, Haiman Christopher A, Hall Per, Halverson Sandra L, Hamann Ute, Hansen Thomas V O, Harter Philipp, Hartikainen Jaana M, Healey Sue, Hein Alexander, Heitz Florian, Henderson Brian E, Herzog Josef, T Hildebrandt Michelle A, Høgdall Claus K, Høgdall Estrid, Hogervorst Frans B L, Hopper John L, Humphreys Keith, Huzarski Tomasz, Imyanitov Evgeny N, Isaacs Claudine, Jakubowska Anna, Janavicius Ramunas, Jaworska Katarzyna, Jensen Allan, Jensen Uffe Birk, Johnson Nichola, Jukkola-Vuorinen Arja, Kabisch Maria, Karlan Beth Y, Kataja Vesa, Kauff Noah, Kelemen Linda E, Kerin Michael J, Kiemeney Lambertus A, Kjaer Susanne K, Knight Julia A, Knol-Bout Jacoba P, Konstantopoulou Irene, Kosma Veli-Matti, Krakstad Camilla, Kristensen Vessela, Kuchenbaecker Karoline B, Kupryjanczyk Jolanta, Laitman Yael, Lambrechts Diether, Lambrechts Sandrina, Larson Melissa C, Lasa Adriana, Laurent-Puig Pierre, Lazaro Conxi, Le Nhu D, Le Marchand Loic, Leminen Arto, Lester Jenny, Levine Douglas A, Li Jingmei, Liang Dong, Lindblom Annika, Lindor Noralane, Lissowska Jolanta, Long Jirong, Lu Karen H, Lubinski Jan, Lundvall Lene, Lurie Galina, Mai Phuong L, Mannermaa Arto, Margolin Sara, Mariette Frederique, Marme Frederik, Martens John W M, Massuger Leon F A G, Maugard Christine, Mazoyer Sylvie, McGuffog Lesley, McGuire Valerie, McLean Catriona, McNeish Iain, Meindl Alfons, Menegaux Florence, Menéndez Primitiva, Menkiszak Janusz, Menon Usha, Mensenkamp Arjen R, Miller Nicola, Milne Roger L, Modugno Francesmary, Montagna Marco, Moysich Kirsten B, Müller Heiko, Mulligan Anna Marie, Muranen Taru A, Narod Steven A, Nathanson Katherine L, Ness Roberta B, Neuhausen Susan L, Nevanlinna Heli, Neven Patrick, Nielsen Finn C, Nielsen Sune F, Nordestgaard Børge G, Nussbaum Robert L, Odunsi Kunle, Offit Kenneth, Olah Edith, Olopade Olufunmilayo I, Olson Janet E, Olson Sara H, Oosterwijk Jan C, Orlow Irene, Orr Nick, Orsulic Sandra, Osorio Ana, Ottini Laura, Paul James, Pearce Celeste L, Pedersen Inge Sokilde, Peissel Bernard, Pejovic Tanja, Pelttari Liisa M, Perkins Jo, Permuth-Wey Jenny, Peterlongo Paolo, Peto Julian, Phelan Catherine M, Phillips Kelly-Anne, Piedmonte Marion, Pike Malcolm C, Platte Radka, Plisiecka-Halasa Joanna, Poole Elizabeth M, Poppe Bruce, Pylkäs Katri, Radice Paolo, Ramus Susan J, Rebbeck Timothy R, Reed Malcolm W R, Rennert Gad, Risch Harvey A, Robson Mark, Rodriguez Gustavo C, Romero Atocha, Rossing Mary Anne, Rothstein Joseph H, Rudolph Anja, Runnebaum Ingo, Salani Ritu, Salvesen Helga B, Sawyer Elinor J, Schildkraut Joellen M, Schmidt Marjanka K, Schmutzler Rita K, Schneeweiss Andreas, Schoemaker Minouk J, Schrauder Michael G, Schumacher Fredrick, Schwaab Ira, Scuvera Giulietta, Sellers Thomas A, Severi Gianluca, Seynaeve Caroline M, Shah Mitul, Shrubsole Martha, Siddiqui Nadeem, Sieh Weiva, Simard Jacques, Singer Christian F, Sinilnikova Olga M, Smeets Dominiek, Sohn Christof, Soller Maria, Song Honglin, Soucy Penny, Southey Melissa C, Stegmaier Christa, Stoppa-Lyonnet Dominique, Sucheston Lara, Swerdlow Anthony, Tangen Ingvild L, Tea Muy-Kheng, Teixeira Manuel R, Terry Kathryn L, Terry Mary Beth, Thomassen Mads, Thompson Pamela J, Tihomirova Laima, Tischkowitz Marc, Toland Amanda Ewart, Tollenaar Rob A E M, Tomlinson Ian, Torres Diana, Truong Thérèse, Tsimiklis Helen, Tung Nadine, Tworoger Shelley S, Tyrer Jonathan P, Vachon Celine M, Van 't Veer Laura J, van Altena Anne M, Van Asperen C J, van den Berg David, van den Ouweland Ans M W, van Doorn Helena C, Van Nieuwenhuysen Els, van Rensburg Elizabeth J, Vergote Ignace, Verhoef Senno, Vierkant Robert A, Vijai Joseph, Vitonis Allison F, von Wachenfeldt Anna, Walsh Christine, Wang Qin, Wang-Gohrke Shan, Wappenschmidt Barbara, Weischer Maren, Weitzel Jeffrey N, Weltens Caroline, Wentzensen Nicolas, Whittemore Alice S, Wilkens Lynne R, Winqvist Robert, Wu Anna H, Wu Xifeng, Yang Hannah P, Zaffaroni Daniela, Pilar Zamora M, Zheng Wei, Ziogas Argyrios, Chenevix-Trench Georgia, Pharoah Paul D P, Rookus Matti A, Hooning Maartje J, Goode Ellen L

机构信息

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

出版信息

Gynecol Oncol. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. Epub 2015 May 2.

DOI:10.1016/j.ygyno.2015.04.034
PMID:25940428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4630206/
Abstract

OBJECTIVE

Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.

METHODS

Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers).

RESULTS

We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations.

CONCLUSIONS

rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.

摘要

目的

基于与卵巢癌和乳腺癌风险增加以及生存时间的关联提示,针对位于KRAS 3'UTR微小RNA结合位点的遗传性变异rs61764370的临床基因检测已商业化。然而,先前强调特定亚组的研究规模相对较小。因此,我们全面评估了与rs61764370相关的卵巢癌和乳腺癌风险以及临床结局。

方法

对卵巢癌协会联盟(15357例卵巢癌患者;30816例对照)、乳腺癌协会联盟(33530例乳腺癌患者;37640例对照)以及BRCA1和BRCA2修饰因子联盟(14765例BRCA1突变携带者和7904例BRCA2突变携带者)纳入的140012名女性进行集中基因分型和分析。

结果

我们发现该变异与卵巢癌风险(OR = 0.99,95%CI 0.94 - 1.04,p = 0.74)或乳腺癌风险(OR = 0.98,95%CI 0.94 - 1.01,p = 0.19)均无关联,并且在突变携带者中结果一致(BRCA1,卵巢癌HR = 1.09,95%CI 0.97 - 1.23,p = 0.14,乳腺癌HR = 1.04,95%CI 0.97 - 1.12,p = 0.27;BRCA2,卵巢癌HR = 0.89,95%CI 0.71 - 1.13,p = 0.34,乳腺癌HR = 1.06,95%CI 0.94 - 1.19,p = 0.35)。在与卵巢癌(HR = 0.94,95%CI 0.83 - 1.07,p = 0.38)、乳腺癌(HR = 0.96,95%CI 0.87 - 1.06,p = 0.38)以及所有其他先前报道的关联方面,也得到了阴性结果。

结论

rs61764370与卵巢癌或乳腺癌风险以及这些癌症患者的临床结局均无关联。因此,对该变异进行基因分型对于这些癌症的预测或管理没有临床实用价值。

相似文献

1
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.KRAS变异体rs61764370对卵巢癌或乳腺癌无临床应用价值。
Gynecol Oncol. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. Epub 2015 May 2.
2
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.KRAS rs61764370 在浸润性上皮性卵巢癌中的作用:对临床检测的影响。
Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8.
3
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.KRAS 3'UTR 中的变异等位基因 rs61764370 T>G 在荷兰 BRCA1、BRCA2 和非 BRCA1/BRCA2 乳腺癌家族中的流行率。
Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30.
4
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.19p13.1 和 ZNF365 位点的常见变异与 BRCA1 和 BRCA2 突变携带者的乳腺癌和卵巢癌的 ER 亚型风险相关。
Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.
5
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.IRS1 中的非同义多态性改变了 BRCA1 突变携带者发生乳腺癌和卵巢癌以及 BRCA2 突变携带者发生卵巢癌的风险。
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1362-70. doi: 10.1158/1055-9965.EPI-12-0229. Epub 2012 Jun 22.
6
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.CASP8 D302H 和 CASP10 V410I 变体与 BRCA1 和 BRCA2 突变携带者的乳腺癌和卵巢癌风险的关联。
Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2859-68. doi: 10.1158/1055-9965.EPI-10-0517. Epub 2010 Oct 26.
7
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.BRCA1 和 BRCA2 基因突变携带者的乳腺癌、卵巢癌和对侧乳腺癌风险。
JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.
8
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.KRAS 变异与发生双重原发性乳腺癌和卵巢癌的风险相关。
PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25.
9
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.KL-VS 序列变异型 Klotho 与 BRCA1 和 BRCA2 突变携带者的癌症风险。
Breast Cancer Res Treat. 2012 Apr;132(3):1119-26. doi: 10.1007/s10549-011-1938-8. Epub 2012 Jan 3.
10
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.多基因风险评分与携带 BRCA1 和 BRCA2 致病性变异的个体的乳腺癌和上皮性卵巢癌风险。
Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15.

引用本文的文献

1
Genetic Variability in the microRNA Binding Sites of and and Risk of Breast Cancer in Colombian Women.哥伦比亚女性中BRCA1和BRCA2的微小RNA结合位点的基因变异性与乳腺癌风险
Onco Targets Ther. 2020 Nov 30;13:12281-12287. doi: 10.2147/OTT.S274431. eCollection 2020.
2
Prognostic Role of mRNA Expression in Breast Cancer.mRNA表达在乳腺癌中的预后作用
J Breast Cancer. 2019 Dec;22(4):548-561. doi: 10.4048/jbc.2019.22.e55.
3
Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.组织特异性 microRNA 表达改变了由 TP53 非编码变异赋予的癌症易感性。
Nat Commun. 2019 Nov 7;10(1):5061. doi: 10.1038/s41467-019-13002-x.
4
Statistical genomics in rare cancer.罕见癌症中的统计基因组学。
Semin Cancer Biol. 2020 Apr;61:1-10. doi: 10.1016/j.semcancer.2019.08.021. Epub 2019 Aug 19.
5
Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics.乳腺癌与微小RNA单核苷酸多态性:微小RNA种系遗传学的重要性
Noncoding RNA. 2019 Mar 20;5(1):27. doi: 10.3390/ncrna5010027.
6
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.在未经选择的复发性和/或转移性头颈癌患者群体中,根据KRAS-LCS6变异情况,在基于铂类-氟尿嘧啶的化疗中添加西妥昔单抗的获益情况。
Eur Arch Otorhinolaryngol. 2019 Feb;276(2):541-550. doi: 10.1007/s00405-018-5235-6. Epub 2018 Dec 6.
7
A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.KRAS 3'非翻译区中一个let-7微小RNA结合位点多态性与北印度人群胆囊癌风险增加及生存率降低相关。
J Cancer Res Clin Oncol. 2016 Dec;142(12):2577-2583. doi: 10.1007/s00432-016-2254-9. Epub 2016 Sep 12.

本文引用的文献

1
Identification of six new susceptibility loci for invasive epithelial ovarian cancer.侵袭性上皮性卵巢癌六个新易感基因座的鉴定。
Nat Genet. 2015 Feb;47(2):164-71. doi: 10.1038/ng.3185. Epub 2015 Jan 12.
2
Don't let the truth get in the way of a good story: an illustration of citation bias in epidemiologic research.别让真相妨碍了精彩的故事:流行病学研究中引用偏倚的一个例证
Am J Epidemiol. 2014 Aug 15;180(4):446-8. doi: 10.1093/aje/kwu164. Epub 2014 Jul 2.
3
Response to Weidhaas and Slack re: Comments on "The role of rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".对魏德哈斯和斯莱克关于《rs61764370在侵袭性上皮性卵巢癌中的作用:对临床检测的启示》评论的回应
Clin Cancer Res. 2011 Oct 15;17(20). doi: 10.1158/1078-0432.CCR-11-1504.
4
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.BRCA1 突变携带者的全基因组关联研究确定了与乳腺癌和卵巢癌风险相关的新位点。
PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.
5
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.鉴定与乳腺癌风险相关的位于 6p24 的 BRCA2 特异性修饰基因座。
PLoS Genet. 2013;9(3):e1003173. doi: 10.1371/journal.pgen.1003173. Epub 2013 Mar 27.
6
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.利用 iCOGS 定制基因分型阵列鉴定 23 个新的前列腺癌易感性位点。
Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi: 10.1038/ng.2560.
7
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.GWAS 荟萃分析和复制确定了三个新的卵巢癌易感性位点。
Nat Genet. 2013 Apr;45(4):362-70, 370e1-2. doi: 10.1038/ng.2564.
8
Large-scale genotyping identifies 41 new loci associated with breast cancer risk.大规模基因分型鉴定出 41 个与乳腺癌风险相关的新位点。
Nat Genet. 2013 Apr;45(4):353-61, 361e1-2. doi: 10.1038/ng.2563.
9
Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.对超过 10000 例病例的分析并未发现先前报道的候选多态性与卵巢癌结局之间存在关联。
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):987-92. doi: 10.1158/1055-9965.EPI-13-0028. Epub 2013 Mar 19.
10
Incorporating genomics into breast and prostate cancer screening: assessing the implications.将基因组学纳入乳腺癌和前列腺癌筛查:评估其影响。
Genet Med. 2013 Jun;15(6):423-32. doi: 10.1038/gim.2012.167. Epub 2013 Feb 14.